search
Back to results

Acid Reflux and Stromal Fibroblasts in Barrett's Esophagus

Primary Purpose

Barrett's Esophagus, GERD

Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Endoscopy and pH study
Sponsored by
Mayo Clinic
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Barrett's Esophagus focused on measuring Barrett's esophagus, GERD

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Prior histological demonstration of Barrett's esophagus that is endoscopically visible; length of visible segment >/= 1 cms
  • Absence of dysplasia on prior biopsies
  • Laboratory studies:

    • Prothrombin time (INR) < 1.5
    • Hemoglobin > 8.0 gm/dL
  • Ability to provide informed consent

Exclusion Criteria:

  • Eastern Cooperative Oncology Group performance status 3 or 4
  • Inability to tolerate endoscopic procedures
  • Pregnancy: Females of child-bearing age will be screened with pregnancy test. Although none of the procedures in the study are contraindicated in pregnancy, sedation used in endoscopy can be contraindicated in early pregnancy
  • Prior esophageal surgery, or cancer

Sites / Locations

  • Mayo Clinic

Outcomes

Primary Outcome Measures

The specific aim of this proposal will be: To assess the association between acid reflux and subepithelial fibroblasts in Barrett's esophagus.

Secondary Outcome Measures

Full Information

First Posted
December 12, 2007
Last Updated
January 16, 2013
Sponsor
Mayo Clinic
Collaborators
AstraZeneca
search

1. Study Identification

Unique Protocol Identification Number
NCT00573911
Brief Title
Acid Reflux and Stromal Fibroblasts in Barrett's Esophagus
Official Title
Acid Reflux and Stromal Fibroblasts in Barrett's Esophagus
Study Type
Interventional

2. Study Status

Record Verification Date
January 2013
Overall Recruitment Status
Completed
Study Start Date
August 2007 (undefined)
Primary Completion Date
January 2011 (Actual)
Study Completion Date
January 2011 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Mayo Clinic
Collaborators
AstraZeneca

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Patients with Barrett's Esophagus are known to have excessive distal esophageal acid exposure comparable to patients with erosive esophagitis. A significant proportion of patients with BE who are not symptomatic on treatment continue to have persistent acid reflux. High dose esomeprazole is able to control acid reflux in patients with BE. The effect of acid reflux on Barrett's esophagus stroma is currently unknown. It is our hypothesis that stromal fibroblast activation in Barrett's esophagus is influenced by acid reflux. The specific aim of this proposal will be: To assess the association between acid reflux and subepithelial fibroblasts in Barrett's esophagus.
Detailed Description
We will conduct a prospective cohort study to assess the degree of stromal activation in patients with LSBE (without dysplasia) who have adequate and inadequate control of acid reflux in the distal esophagus. The study will be conducted in two phases. Phase 1 (Pilot): 20 patients with LSBE without dysplasia will undergo endoscopy with biopsies and a 24 hour pH study on treatment. Patients will then be divided into 2 groups: Group A (GER): Those with ongoing acid reflux (characterized by either presence of esophagitis [LA classification B,C or D1] on endoscopy, and/or a positive pH study on treatment defined using standard criteria) Group B (NGER): Those with controlled acid reflux (negative endoscopy and pH study on treatment). Stromal markers that will be assessed and compared between the 2 groups will include: presence of activated myofibroblasts (detected by immunohistochemistry for vimentin and smooth muscle actin).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Barrett's Esophagus, GERD
Keywords
Barrett's esophagus, GERD

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
16 (Actual)

8. Arms, Groups, and Interventions

Intervention Type
Procedure
Intervention Name(s)
Endoscopy and pH study
Intervention Description
endoscopy and PH study done one time
Primary Outcome Measure Information:
Title
The specific aim of this proposal will be: To assess the association between acid reflux and subepithelial fibroblasts in Barrett's esophagus.
Time Frame
end of study

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Prior histological demonstration of Barrett's esophagus that is endoscopically visible; length of visible segment >/= 1 cms Absence of dysplasia on prior biopsies Laboratory studies: Prothrombin time (INR) < 1.5 Hemoglobin > 8.0 gm/dL Ability to provide informed consent Exclusion Criteria: Eastern Cooperative Oncology Group performance status 3 or 4 Inability to tolerate endoscopic procedures Pregnancy: Females of child-bearing age will be screened with pregnancy test. Although none of the procedures in the study are contraindicated in pregnancy, sedation used in endoscopy can be contraindicated in early pregnancy Prior esophageal surgery, or cancer
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Prasad G Iyer, M.D.
Organizational Affiliation
Mayo Clinic
Official's Role
Principal Investigator
Facility Information:
Facility Name
Mayo Clinic
City
Rochester
State/Province
Minnesota
ZIP/Postal Code
55905
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Acid Reflux and Stromal Fibroblasts in Barrett's Esophagus

We'll reach out to this number within 24 hrs